Telix and ITM Agree Transformational Radiopharmaceutical Merger

Company Telix Pharmaceuticals / ITM Isotope Technologies Munich Event Type Acquisition Modality Radiopharmaceutical Isotope Supply, Manufacturing and Therapeutics Asset ITM 11 (Lutetium-177 Somatostatin Receptor Therapy) Plus Isotope Manufacturing Platform Target Not Applicable (Corporate Transaction) Disease Area Neuroendocrine Tumors and Broader Radiopharmaceutical Oncology Summary Telix agreed…